

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM405075

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Reliable Biopharmaceutical Corporation		11/02/2016	Corporation: MISSOURI
RECEIVING PARTY DATA			
Name:	Reliable Biopharmaceutical, LLC		
Street Address:	Radnor Corporate Center, 100 Matsonford Road		
Internal Address:	Building One, Suite 200		
City:	Radnor		
State/Country:	PENNSYLVANIA		
Postal Code:	19087		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	1926201	R RELIABLE BIOPHARMACEUTICAL	
Registration Number:	4621993	REACTION READY	
Registration Number:	5054407	HPI	
Serial Number:	75148814	MALTODAPOH	
CORRESPONDENCE DATA			
Fax Number:	2159882757		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	karen.spina@dbr.com		
Correspondent Name:	Robert E. Cannuscio		
Address Line 1:	One Logan Square, Ste. 2000		
Address Line 2:	Drinker Biddle & Reath LLP		
Address Line 4:	Philadelphia, PENNSYLVANIA 19103-6996		
NAME OF SUBMITTER:	Robert E. Cannuscio		
SIGNATURE:	/Robert E. Cannuscio/		
DATE SIGNED:	11/10/2016		
Total Attachments: 8			
source=Assignment#page1.tif			

OP \$115.00 1926201

source=Assignment#page2.tif
source=Assignment#page3.tif
source=Assignment#page4.tif
source=Assignment#page5.tif
source=Assignment#page6.tif
source=Assignment#page7.tif
source=Assignment#page8.tif

INTELLECTUAL PROPERTY ASSIGNMENT

This Intellectual Property Assignment (the "Assignment"), dated as of November 2, 2016 (the "Effective Date"), by and between Reliable Biopharmaceutical, LLC, a Delaware limited liability company ("Assignee"), and Reliable Biopharmaceutical Corporation, a Missouri corporation ("Assignor") pursuant to a Bill Of Sale And Assignment And Assumption Agreement dated as of December 1, 2015 by and between Assignor and Assignee ("Bill of Sale"). Capitalized terms appearing herein will have the meanings ascribed to them in the Bill of Sale. The Assignor and Assignee are hereinafter referred to collectively as the "Parties" and sometimes each individually as a "Party."

WHEREAS, under the terms of the Bill of Sale, Assignor has agreed to convey, transfer and assign to Assignee, among other assets, certain intellectual property of Assignor, and has agreed to execute and deliver this Assignment, for recording with the United States Patent and Trademark Office.

NOW, THEREFORE, for and in consideration as set forth in the Bill of Sale, and other good and valuable consideration, the receipt of which is hereby acknowledged, Assignor and Assignee agree as follows:

Assignor irrevocably hereby assigns, transfers, conveys and delivers unto Assignee any and all right, title and interest held by or licensed to Assignor in and to all the intellectual property acquired by Assignee pursuant to the Bill of Sale, including the following throughout the world (collectively, "Intellectual Property");

- (i) all inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents, patent applications, and patent disclosures, together with all reissuances, continuations, continuations-in-part, revisions, extensions, and reexaminations thereof, including all patents and patent applications in Schedule A;
- (ii) all trademarks, service marks, trade dress, logos, trade names, and other indications of origin, and all corporate names, including all goodwill associated therewith, and all applications, registrations, and renewals in connection therewith in any jurisdiction, including all registrations and applications in Schedule B;
- (iii) all copyrights and works of authorship (whether copyrightable or not), and all applications, registrations, and renewals in connection therewith in any jurisdiction;
- (iv) all trade secrets;
- (v) all software;
- (vi) all websites, website content, URLs, and domain names (including registrations thereof);
- (vii) all social media accounts; and
- (viii) all other intellectual property and/or proprietary rights;

(ix) all rights of any kind whatsoever of Assignor accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions and otherwise throughout the world;

(x) all tangible embodiments of any of the foregoing (in whatever form or medium), including all copies thereof;

(xi) any and all royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and

(xii) any and all claims and causes of action, with respect to any of the foregoing, whether accruing before, on and/or after the date hereof, including all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for past, present and future infringement, dilution, misappropriation, violation, misuse, breach or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

All rights in, to and under the Intellectual Property to be held and enjoyed by Assignee to the same extent as would have been held and enjoyed by Assignor had this sale, assignment and transfer not been made; any and all rights to royalties, profits, compensations, license fees or other payments or remuneration of any kind relating to the Intellectual Property from the Effective Date; and all claims or causes of action such Assignors have or may have in connection with the Intellectual Property, including, but not limited to, the right to sue and recover damages for any and all past infringements of any of the Intellectual Property.

Assignor covenants and agrees that Assignor shall, at the request of Assignee or its counsel, execute, acknowledge and deliver all such further acts, deeds, assignments, transfers, powers of attorney and assurances as may be required to carry out the intent of this Assignment, and to transfer and vest title to and in the Intellectual Property and to procure, maintain, enforce and protect the right, title and interest in and enjoyment of all of the Intellectual Property assigned, transferred and conveyed to Assignee pursuant to this Assignment; provided, however, this Assignment shall be effective regardless of whether any such additional documents are executed. Assignor agrees to cooperate with Assignee to initiate the transfer process in relation to the domain names and social media accounts electronically from Assignor's accounts to Assignee's accounts, as soon as practicable.

Assignor further authorizes the Commissioner of Patents and Trademarks of the United States, and any official of any country foreign to the United States, whose duty it is to record intellectual property registrations, applications and title thereto, to record the title thereto as the property of Assignee, its legal representatives, successors and assigns and to issue all patents for improvements therein to Assignee, in accordance with the terms of this Assignment. Assignor authorizes and requests the applicable registration authority and social media entities to transfer the domain names and social media accounts from Assignor to Assignee.

Relationship with the Bill of Sale. This Assignment is intended to evidence the consummation of certain of the transactions contemplated by the Bill of Sale. This Assignment is made without representation or warranty except as provided in and by the Bill of Sale. This Assignment is in all respects subject to the provisions of the Bill of Sale and is not intended in

any way to supersede, limit or qualify any provision of the Bill of Sale, except that, to the extent that they conflict, the Schedules attached to this Assignment shall take precedence over the schedules to the Bill of Sale for purposes of this Assignment.

This Assignment shall be binding upon and shall inure to the benefit of Assignor and Assignee and their respective successors, legal representatives and assigns, and all others acting by, through, with or under the Assignor's direction and all those in privity therewith.

This Assignment shall be governed by, and construed in accordance with (i) the laws of the United States, in respect to trademark and patent issues; and (ii) in all other respects, including as to validity (except for patent and trademark issues), interpretation and effect, by the laws of the State of Delaware without giving effect to the conflict of laws rules thereof.

A facsimile or photocopied signature (which may be delivered by facsimile or other electronic means) shall be deemed to be the functional equivalent of an original for all purposes.

[Signature page follows]

IN WITNESS WHEREOF, the Parties have caused this Intellectual Property Assignment to be duly executed as of the Effective Date.

ASSIGNOR:

Reliable Biopharmaceutical Corporation

By *[Signature]*
Name: Michael Beckett
Title: Secretary

ASSIGNEE:

Reliable Biopharmaceutical, LLC

By _____
Name: David Feldker
Title: President and CEO



ACKNOWLEDGMENT

STATE OF Virginia)
COUNTY OF Fairfax)

This instrument was acknowledged before me this 2 day of November, 2016 by Michael Beckett, as Secretary of Reliable Biopharmaceutical Corporation on behalf of such entity.

Rachel Krom Lopes
Notary Public in and for the State of Virginia

STATE OF _____)
COUNTY OF _____)

This instrument was acknowledged before me this _____ day of _____, 2016 by David Feldker, as President and CEO of Reliable Biopharmaceutical Corporation on behalf of such entity.

Notary Public in and for the State of _____

IN WITNESS WHEREOF, the Parties have caused this Intellectual Property Assignment to be duly executed as of the Effective Date.

ASSIGNOR:

Reliable Biopharmaceutical Corporation

By _____
Name: Michael Beckett
Title: Secretary

ASSIGNEE:

Reliable Biopharmaceutical, LLC

By David Feldker
Name: David Feldker
Title: President and CEO

ACKNOWLEDGMENT


STATE OF _____)
COUNTY OF _____)

This instrument was acknowledged before me this _____ day of _____, 2016 by Michael Beckett, as Secretary of Reliable Biopharmaceutical Corporation on behalf of such entity.

Notary Public in and for the State of _____

STATE OF Missouri)
COUNTY OF St. Louis)

This instrument was acknowledged before me this 3 day of November, 2016 by David Feldker, as President and CEO of Reliable Biopharmaceutical Corporation on behalf of such entity.




Katherine S. Prisha
Notary Public in and for the State of Missouri

SCHEDULE A

Country	Title	Application No.	Filing Date	Patent No.	Grant Date
US	Sulfated Acid Amides Having Anticoagulant Properties	08/040,112	3/30/1993	5,589,588	12/31/1996
US	Sulfated Acid Amides Having Anticoagulant Properties	08/538,628	10/4/1995	5,714,598	2/3/1998
US	Process for the Production of 2-Halo-6-Aminopurine Derivatives	09/274,518	3/23/1999	6,282,061	6/26/2001
US	Process for the Production of 2-Halo-6-Aminopurine Derivatives	09/803,765	3/12/2001	6,596,858	7/22/2003
US	Process for the Production of Pentostatin Aglycone and Pentostatin	10/734,545	12/12/2003	7,393,954	7/1/2008
US	Process for Preparing Fondaparinux Sodium and Intermediates Useful in the Synthesis Thereof	12/847,719	7/30/2010	8,288,515	10/16/2012
US	Process for Preparing Fondaparinux Sodium and Intermediates Useful in the Synthesis Thereof	13/618,786	9/14/2012	8,703,923	04/22/2014
US	Process for Preparing Fondaparinux Sodium and Intermediates Useful in the Synthesis Thereof	14/256,235	04/18/2014		
US	Efficient and Scalable Process for the Manufacture of Fondaparinux Sodium	12/915,854	10/29/2010	8,420,790	4/16/2013

US	Efficient and Scalable Process for the Manufacture of Fondaparinux Sodium	13/791,178	3/8/2013	8,987,430	10/14/2014
US	Improved Processes for the Preparation of Regadenoson and a New Crystalline Form Thereof	14/112,173	11/1/13	8,859,522	10/14/2014
PCT	Process for the Production of 2-Halo-6-Aminopurine Derivatives	PCT US10-43946	7/30/2010		
CA	Process for Preparing Fondaparinux Sodium and Intermediates Useful in the Synthesis Thereof	2,777,099	7/30/2010		
EP	Process for Preparing Fondaparinux Sodium and Intermediates Useful in the Synthesis Thereof	10740809.8	7/30/2010		
IN	Process for Preparing Fondaparinux Sodium and Intermediates Useful in the Synthesis Thereof	1822 DELNP/2012	7/30/2010		
PCT	Efficient and Scalable Process for the Manufacture of Fondaparinux Sodium	PCT US12-23610	2/2/2012		
CA	Efficient and Scalable Process for the Manufacture of Fondaparinux Sodium	2,862,606	02/02/2012		
EP	Efficient and Scalable Process for the Manufacture of Fondaparinux Sodium	12706726.2	02/02/2012		

Schedule B

	Registration No.	Registration Date	Serial Number	Filing Date
 Reliable Biopharmaceutical R RELIABLE BIOPHARMACEUTICAL	1926201	1/0/10/1995	74443353	10/4/1993
REACTION READY	4621993	10/14/2014	85940421	5/23/2013
HPI	5054407	10/4/2016	86921564	2/26/2016
MALTODAPOH			75148814	8/12/1996